校内科研机构(虚体)
北京大学眼科中心
阅读次数: 发布日期:2019-11-12
机构概况
北京大学眼科中心是2001年由北京大学医学部成立,北医三家附属医院眼科参与,依托单位是北京大学第三医院。第一任中心主任是曹安民教授,接着是林顺潮教授、黎晓新教授分别接任眼科中心主任。中心工作围绕眼科科研展开,依托研究项目和两个北京市重点实验室,形成PI团队,同时尝试引进其他学科PI,形成交叉融合。配合北京大学临床+X和“985”平台建设经费,开展眼科学领域的研究和青年人才培养。
研究领域及方向
贯彻国家卫健委““十四五”眼健康规划”制定以下研究方向:
1. 机制研究:青光眼、中浆、年龄相关性黄斑变性、视网膜退行性病变、视网膜肿瘤
2. 精准诊断与干预策略:眼底血管性疾病、遗传性眼病
3. 临床检测与组学研究:感染性眼病、免疫性眼病、干眼
4. 近视研究:脉络膜血流灌注与近视进展、近视眼的生物力学研究
5. 临床眼病/罕见病队列研究
6. 视觉形成与重塑研究、评估与康复
7. 再生医学与组织工程:视网膜病、青光眼、角膜病
8. 人工智能/材料科学:人工智能的疾病诊断与筛查策略、人工眼内填充材料研发
近年来的重要科研成果及贡献
1. 洪晶教授获得2018年度高等院校科技进步二等奖:角膜内皮移植术技术的创新及
2. 张纯教授获得2022年度北京市科技进步二等奖:青光眼精准诊治体系的建立
3. 黎晓新教授团队系统性揭示了年龄相关性黄斑变性的发病机制以及干预靶点
4. 赵明威教授团队探索了年龄相关性黄斑变性的发病新机制
5. 张纯教授团队与清华大学化学系刘东生教授团队合作利用DNA 超分子水凝胶研发人工玻璃体替代物
6. 齐虹教授团队发现角膜源性PEDF在干眼中发挥负向免疫调节作用
7. 洪晶教授团队成功建立巨细胞病毒眼前节炎症动物模型
8. 梁建宏教授团队提出早产儿视网膜病变发生机制及干预策略
9. 冯云教授团队启动临床试验:人胚干细胞源M细胞治疗眼表碱烧伤的安全性及有效性研究
10. 杨丽萍教授团队基因编辑治疗遗传性视网膜变性,知识产权成功转化1000万
11. 王乐今教授团队成功研发植入式青光眼微引流仪和植入式眼部神经肌肉刺激器
12. 吴慧娟教授发明专利:一种新型青光眼引流植入装置及系统成果转化
机构负责人:黎晓新教授
联系人:张纯教授
邮箱:zhangc1@yahoo.com
电话:18601031059
地址:北京大学第三医院
Peking University Eye Center
The Peking University Eye Center was established in 2001 by the Peking University Health Science Center, with participation from the ophthalmology departments of its three affiliated hospitals, and is based at Peking University Third Hospital. The first director of the center was Professor Mark OM Tso, followed by Professor Dennis Lam and Professor Li Xiaoxin. The center's work focuses on ophthalmic research, relying on research projects and two Beijing Key Laboratories to form PI teams, while also attempting to introduce PIs from other disciplines to create interdisciplinary integration. Supported by the Peking University “Clinic + X” and the "985" platform construction funds, the center conducts research in the field of ophthalmology and cultivates young talent.
In line with the Ministry of Health’s "14th Five-Year National Plan for Eye Health," the following research directions have been established:
1. Mechanism Research: glaucoma, central serous chorioretinopathy, age-related macular degeneration, retinal degenerative diseases, retinal tumors.
2. Precision Diagnosis and Intervention Strategies: fundus vascular diseases, hereditary eye diseases.
3. Clinical Testing and Omics Research: infectious eye diseases, immune-related eye diseases, dry eye.
4. Myopia Research: choroidal blood flow perfusion and myopia progression, biomechanics of myopic eyes.
5. Clinical Eye Disease/Rare Disease Cohort Studies.
6. Research on Visual Formation and Remodeling, Assessment, and Rehabilitation.
7. Regenerative Medicine and Tissue Engineering: retinal diseases, glaucoma, corneal diseases.
8. Artificial Intelligence/Materials Science: AI disease diagnosis and screening strategies, development of artificial intraocular filling materials.
Recent significant research achievements and contributions include:
1. Professor Hong Jing received the 2018 Higher Education Science and Technology Progress Award (Second Prize) for innovations in corneal endothelial transplantation techniques.
2. Professor Zhang Chun received the 2022 Beijing Science and Technology Progress Award (Second Prize) for establishing a precise diagnosis and treatment system for glaucoma.
3. Professor Li Xiaoxin's team systematically revealed the pathogenesis and intervention targets of age-related macular degeneration.
4. Professor Zhao Mingwei's team explored new mechanisms of age-related macular degeneration.
5. Professor Zhang Chun's team collaborated with Professor Liu Dongsheng from Tsinghua University's Department of Chemistry to develop an artificial vitreous substitute using DNA supramolecular hydrogels.
6. Professor Qi Hong's team discovered that corneal-derived PEDF plays a negative immunomodulatory role in dry eye.
7. Professor Hong Jing's team successfully established an animal model of anterior segment inflammation caused by cytomegalovirus.
8. Professor Liang Jianhong's team proposed mechanisms and intervention strategies for retinopathy of prematurity.
9. Professor Feng Yun's team initiated clinical trials on the safety and efficacy of M cell therapy
Director: Professor Li Xiaoxin
Contact: Professor Zhang Chun
Email: zhangc1@yahoo.com
TEL: 18601031059
Address: 49 North Garden Rd., Haidian, Peking University Third Hospital, 100191